|
Please
download and print the PDF file below:
|
|
|
|
Kristin Larson, MSN, ANP, GNP, CNN
|
Kristin Larson, MSN, ANP, GNP, CNN, is a
Nephrology Nurse Practitioner, Nephrology
Associates, Salt Lake City, UT. She is the
Chairperson of ANNA’s Health Policy Committee
and a member of the Intermountain Chapter.
|
Anemia management practices in patients on hemodialysis that incorporate a balanced
approach to erythropoiesis-stimulating agent (ESA) and intravenous (IV) iron therapy,
use the lowest effective dose of ESA, and provide IV iron therapy in patients with higher
serum ferritin levels have become important treatment considerations. This case study,
followed by an indepth discussion, addresses these issues and helps to identify safe and
effective treatment strategies to assist nurses in improving patient outcomes.
|
|
CE
RELATED INFORMATION |
|
This
offering for 1.5 contact
hours is being provided by
the
American
Nephrology Nurses Association
(ANNA), which
is accredited as a provider
and approver of continuing
education in nursing by
the American Nurses
Credentialing Center-Commission
on Accreditation (ANCCCOA).
This educational activity
is approved by most states
and specialty organizations
that recognize the ANCC-COA
accreditation process. ANNA
is an approved provider of
continuing education in nursing
by the California Board of
Registered Nursing, BRN Provider
No. 00910; and the Kansas
State Board of Nursing, Provider
No. LT0148-0738. This offering
is accepted for RN and LPN
relicensure in Kansas.
|
|
Goal:
To identify anemia management practices for safely and effectively achieving appropriate
hemoglobin (Hb) targets, reducing ESA requirements, addressing elevated
serum ferritin levels, and overcoming obstacles to effective erythropoiesis.
Objectives:
1. Evaluate a case study involving an increase in maintenance IV iron to improve Hb
levels and overall patient outcomes.
2. Understand how to interpret updated KDOQI and FDA recommendations that
address emerging information about ESAs, Hb targets, IV iron, and patients with
elevated serum ferritin levels.
3. Discuss the relevance of this information for treating patients on hemodialysis
who have anemia and recent evidence that IV iron administration is an effective
solution for such patients.
|
AUTHOR DISCLOSURE
STATEMENT |
Kristin Larson
has no conflicts of interest to disclose.
|
ANNA and HDCN CE POLICY STATEMENTS |
The CE policy and disclosure statements of the American Nephrology
Nurses' Association are given in detail on the Symposium
Home Page. The CE policy statements of HDCN are listed on
this page. |